We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+33.14%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7.1B
AUM Growth
+$1.15B
Cap. Flow
-$108M
Cap. Flow %
-1.52%
Top 10 Hldgs %
31.14%
Holding
166
New
24
Increased
29
Reduced
28
Closed
31

Top Buys

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$130M
2
RPTX
Repare Therapeutics
RPTX
+$110M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$93.3M
4
BIIB icon
Biogen
BIIB
+$70.8M
5
TBPH icon
Theravance Biopharma
TBPH
+$60.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
PFE icon
Pfizer
PFE
+$98.3M
3
GILD icon
Gilead Sciences
GILD
+$98M
4
ALEC icon
Alector
ALEC
+$64.9M
5
HCA icon
HCA Healthcare
HCA
+$63.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 1.61%
3 Miscellaneous 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
126
InflaRx
IFRX
$312M
$3.11M 0.04%
678,525
-389,075
-36% -$2.52M
ARWR icon
127
Arrowhead Research
ARWR
$11.4B
$2.94M 0.04%
68,100
– –
CRBP icon
128
PUT
Corbus Pharmaceuticals
CRBP
$156M
$2.94M 0.04%
+11,667
New +$2.36M
NTLA icon
129
Intellia Therapeutics
NTLA
$1.66B
$2.88M 0.04%
137,100
-125,000
-48% -$2.12M
CRIS icon
130
Curis
CRIS
$2.72M
$1.5M 0.02%
3,104
-292
-9% -$108K
ELDN icon
131
Eledon Pharmaceuticals
ELDN
$225M
$1.46M 0.02%
176,851
– –
BMY.RT
132
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.25M 0.02%
350,000
– –
YARW
133
Yarrow Bioscience
YARW
$72.1M
$1.03M 0.01%
165
-321
-66% -$2.17M
ARVN icon
134
Arvinas
ARVN
$549M
$986K 0.01%
29,400
-965,600
-97% -$41M
BLRX
135
BioLineRX
BLRX
$12.2M
$118K ﹤0.01%
1,731
– –
ADAP
136
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,525,654
Closed -$6.87M
APLS
137
DELISTED
Apellis Pharmaceuticals
APLS
– –
-50,485
Closed -$1.35M
ARGX icon
138
argenx
ARGX
$61.6B
– –
-28,591
Closed -$3.77M
ATXS
139
DELISTED
Astria Therapeutics
ATXS
– –
-7,400
Closed -$184K
BHC icon
140
Bausch Health
BHC
$2.21B
– –
-2,399,880
Closed -$37.2M
BMRN icon
141
BioMarin Pharmaceuticals
BMRN
$12.9B
– –
-540,500
Closed -$45.7M
BTAI
142
DELISTED
BioXcel Therapeutics
BTAI
– –
-6,706
Closed -$2.4M
HCA icon
143
HCA Healthcare
HCA
$92.4B
– –
-709,800
Closed -$63.8M
KALV
144
DELISTED
KalVista Pharmaceuticals
KALV
– –
-420,641
Closed -$3.22M
MBIO icon
145
Mustang Bio
MBIO
$3.84M
– –
-336
Closed -$675K
NGNE icon
146
Neurogene
NGNE
$705M
– –
-46,090
Closed -$10.5M
PFE icon
147
CALL
Pfizer
PFE
$158B
– –
-527,000
Closed -$16.3M
PFE icon
148
Pfizer
PFE
$158B
– –
-3,174,753
Closed -$98.3M
PTCT icon
149
PTC Therapeutics
PTCT
$5.55B
– –
-1,148,723
Closed -$51.2M
PTGX icon
150
Protagonist Therapeutics
PTGX
$9.56B
– –
-66,909
Closed -$472K
3 4 5
6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2020 Portfolio in Review

As of Q2 2020, OrbiMed held 166 positions worth $7.1B, up 19% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed's Q2 2020 filing shows 24 new, 29 increased, 28 reduced and 31 closed positions. Its largest new stake was Burning Rock Biotech: 474,607 shares worth $128M. The largest sale was Ascendis Pharma A/S, an estimated $237M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q2 2020 buy was Burning Rock Biotech: 474,607 shares worth $128M.
  • OrbiMed added most to Biogen in Q2 2020, an estimated $70.8M increase.
  • OrbiMed's biggest Q2 2020 reduction was Ascendis Pharma A/S, cutting an estimated $237M.
  • OrbiMed fully exited Pfizer in Q2 2020, selling an estimated $98.3M.
  • OrbiMed's ten largest holdings make up 31% of its $7.1B portfolio in Q2 2020.
  • OrbiMed opened 24 new positions and closed 31 in Q2 2020.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $7.1B.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.